South Wales, Sept. 11 -- United Kingdom Intellectual Property Office (UKIPO) has registered trademark "KUVOVDA" on Aug. 28. The details about the trademark application no. UK00004437444 published in the journal no. 2026/037 (Sept. 11).
With Bryers Intellectual Property Ltd as representative, Hong Kong King-Friend, Industrial Company, Ltd. filed the trademark application for the below mentioned good(s)/service(s).
Class 5 : Pharmaceuticals; pharmaceutical preparations; pharmaceutical products; biologics; biosimilars; pegfilgrastim biosimilars; pharmaceutical preparations for the treatment of neutropenia; pharmaceutical preparations for the treatment of low white blood cells; pharmaceutical preparations for use in stimulating white blood cell production; biosimilars for use in stimulating white blood cell production; pharmaceutical preparations, namely, recombinant-human granulocyte-CSF for use in stimulating white blood cell production; recombinant-human granulocyte-CSF biosimilars for use in stimulating white blood cell production; pharmaceutical preparations, namely, injectable pegfilgrastim biosimilars; pharmaceutical preparations, namely, injectable biosimilars for the treatment of neutropenia; pharmaceutical preparations, namely, injectable biosimilars for the treatment of low white blood cells; pharmaceutical preparations, namely, injectable biosimilars for use in stimulating white blood cell production; pharmaceutical preparations, namely, injectable recombinant-human granulocyte-CSF for use in stimulating white blood cell production; pharmaceutical preparations, namely, injectable recombinant-human granulocyte-CSF biosimilars for use in stimulating white blood cell production; injectors sold filled with pegfilgrastim biosimilars; injectors sold filled with pharmaceutical preparations for the treatment of neutropenia; injectors sold filled with pharmaceutical preparations for the treatment of low white blood cells; injectors sold filled with pharmaceutical preparations for use in stimulating white blood cell production; injectors sold filled with biosimilars for use in stimulating white blood cell production; injectors sold filled with recombinant-human granulocyte-CSF for use in stimulating white blood cell production; injectors sold filled with recombinant-human granulocyte-CSF biosimilars for use in stimulating white blood cell production.
Class 42 : Providing information in the field of scientific and medical research related to pharmaceuticals; providing information in the field of scientific and medical research related to cancer and cancer treatments; research and development of pharmaceuticals; research and development of pharmaceuticals in the field of cancer and cancer treatments.
Class 44 : Providing medical information; providing health information; providing medical information in the field of cancer and cancer treatments; providing health information in the field of cancer and cancer treatments; medical and pharmaceutical consultation; pharmaceutical advice; providing information to patients in the field of administering medications; individual medical counseling services provided to patients; providing personal support services for families of patients with life threatening disorders, namely, health counseling services.
The original document can be viewed at: http://www.ipo.gov.uk/cgi-bin/redirect.cgi?type=tmj&link=6¶m1=UK00004437444
Disclaimer: Curated by HT Syndication.
